TG Therapeutics, Inc.
TGTX
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), anā¦ read more
Healthcare
Biotechnology
16 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$55.39
Price+1.36%
$0.74
1Y
Price
Market Cap
$8.479b
Mid
Price/Earnings 3y Avg5y Avg
20.1x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+9.0%
EBITDA Margin+3.2%
Net Profit Margin+8.8%
Free Cash Flow Margin+9.0%
EBITDA Margin+3.2%
Net Profit Margin+8.8%
Free Cash Flow MarginRevenue
$799.536m
+29.7%
1y CAGR+52.6%
3y CAGR+2112.0%
5y CAGREarnings
$441.490m
-1.3%
1y CAGR+631.9%
3y CAGR+500.3%
5y CAGREPS
$2.74
-1.1%
1y CAGR+604.1%
3y CAGR+479.6%
5y CAGRBook Value
$604.083m
$1.640b
Assets$1.036b
Liabilities$754.441m
DebtDebt to Assets
46.0%
5.6x
Debt to EBITDAFree Cash Flow
-$560k
+97.8%
1y CAGR+35.7%
3y CAGR+47.3%
5y CAGRNo items found.
Press Releases
Statements and updates from the company